Chan Dong Yeom, et al. is needed for the development of more accurate diagnostic tool of identifying Asian men with clinically IPCa. The incidence of IPCa after prostate biopsy showed an increase with time. However, the Epstein criteria may not be validly applicable in Korean PCa patients because the inaccuracy rate of the criteria was as high as 42.1%. A modi- fied diagnostic tool for active surveillance is necessary for Korean PCa patients. REFERENCES 1. Chun FK, Briganti A, Gallina A, Hutterer GC, Shariat SF, Antebie E, et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 2007;52: 1067-74. 2. Yin M, Bastacky S, Chandran U, Becich MJ, Dhir R. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol 2008;179:892-5. 3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74. 4. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analy- sis. Cancer 2004;101:2001-5. 5. Chung JS, Choi HY, Song HR, Byun SS, Seo SI, Song C, et al. Nomogram to predict insignificant prostate cancer at radical pros- tatectomy in Korean men: a multi-center study. Yonsei Med J 2011;52:74-80. 6. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, et al. Ap- plication of the Epstein criteria for prediction of clinically insignif- icant prostate cancer in Korean men. BJU Int 2010;105:1526-30. 7. Hekal IA, El-Tabey NA, Nabeeh MA, El-Assmy A, Abd El-Ha- meed M, Nabeeh A, et al. Validation of Epstein criteria of insignif- icant prostate cancer in Middle East patients. Int Urol Nephrol 2010;42:667-71. 8. Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recur- rence after radical prostatectomy. Eur J Cancer 2007;43:536-43. 9. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally di- rected biopsies for the detection of prostate cancer. J Urol 2001;165:1554-9. 10. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC. Mor- phometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989;141:341-5. 11. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific anti- gen density. J Urol 2003;170(2 Pt 1):370-2. 12. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306-13. 13. Song C, Ro JY, Lee MS, Hong SJ, Chung BH, Choi HY, et al. Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology 2006;68:820-4. 14. Man A, Pickles T, Chi KN; British Columbia Cancer Agency Prostate Cohort Outcomes Initiative. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. J Urol 2003;170:901-4. 15. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free tes- tosterone a marker for high grade prostate cancer? J Urol 2000; 163:824-7. 16. Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, et al. Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL. Urology 2010;76:919-22. 17. Sokoloff MH, Yang XJ, Fumo M, Mhoon D, Brendler CB. Char- acterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL. BJU Int 2004;93:499-502. 18. Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Toch- ner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 2004;164:1227-30. 19. Chun FK, Steuber T, Erbersdobler A, Currlin E, Walz J, Schlomm T, et al. Development and internal validation of a nomogram pre- dicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-6. 20. Singh J, Trabulsi EJ, Gomella LG. Is there an optimal management for localized prostate cancer? Clin Interv Aging 2010;5:187-97. 362 Yonsei Med J http://www.eymj.org Volume 53 Number 2 March 2012